Cipla ended with a gain of over 3% to Rs 281. The counter saw a near five-fold surge in its two-week average traded quantity of shares. Over 1 million shares were traded as against its two-week average of 236,217 shares.
_______________________________________________________________ (Updated 1257 hrs)
India's Cipla is one of the very few companies in the world which can produce Tamiflu drug to prevent and to treat the global swine flu outbreak.
According to reports, Cipla has the capacity to supply upto 1.5 million doses of the Tamiflu drug to prevent the spread and for the treatment of swine flu.
The stock today opened at Rs 276 and then zoomed to a high of Rs 294. The scrip is now at Rs 294, up 8% from the previous close. Around 701,120 shares have been traded on the BSE as against the two-week daily average traded volume of 232,617 shares.
Content Guide
